BRPI0514377A - derivados tricìclicos fundidos para o tratamento de distúrbios psicóticos - Google Patents

derivados tricìclicos fundidos para o tratamento de distúrbios psicóticos

Info

Publication number
BRPI0514377A
BRPI0514377A BRPI0514377-2A BRPI0514377A BRPI0514377A BR PI0514377 A BRPI0514377 A BR PI0514377A BR PI0514377 A BRPI0514377 A BR PI0514377A BR PI0514377 A BRPI0514377 A BR PI0514377A
Authority
BR
Brazil
Prior art keywords
treatment
psychotic disorders
fused tricyclic
tricyclic derivatives
disorders
Prior art date
Application number
BRPI0514377-2A
Other languages
English (en)
Portuguese (pt)
Inventor
Jonathan Bentley
Markus Bergauer
Barbara Bertani
Matteo Biagetti
Manuela Borriello
Steven Mark Bromidge
Massimo Gianotti
Enrica Granci
Colin Philip Leslie
Alessandra Pasquarello
Valeria Zucchelli
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0419315A external-priority patent/GB0419315D0/en
Priority claimed from GB0507386A external-priority patent/GB0507386D0/en
Priority claimed from GB0515010A external-priority patent/GB0515010D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of BRPI0514377A publication Critical patent/BRPI0514377A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
BRPI0514377-2A 2004-08-31 2005-08-29 derivados tricìclicos fundidos para o tratamento de distúrbios psicóticos BRPI0514377A (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0419315A GB0419315D0 (en) 2004-08-31 2004-08-31 Compounds
GB0507386A GB0507386D0 (en) 2005-04-12 2005-04-12 Compounds
GB0515010A GB0515010D0 (en) 2005-07-21 2005-07-21 Compounds
PCT/EP2005/009379 WO2006024517A1 (en) 2004-08-31 2005-08-29 Fused tricyclic derivatives for the treatment of psychotic disorders

Publications (1)

Publication Number Publication Date
BRPI0514377A true BRPI0514377A (pt) 2008-06-24

Family

ID=35106764

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0514377-2A BRPI0514377A (pt) 2004-08-31 2005-08-29 derivados tricìclicos fundidos para o tratamento de distúrbios psicóticos

Country Status (17)

Country Link
US (1) US20120022056A1 (2)
EP (1) EP1786822A1 (2)
JP (1) JP2008511574A (2)
KR (1) KR20070057885A (2)
CN (1) CN101048414B (2)
AR (1) AR053307A1 (2)
AU (1) AU2005279278A1 (2)
BR (1) BRPI0514377A (2)
CA (1) CA2578781A1 (2)
IL (1) IL181387A (2)
MA (1) MA28871B1 (2)
MX (1) MX2007002548A (2)
NO (1) NO20071326L (2)
NZ (1) NZ553506A (2)
PE (1) PE20060653A1 (2)
TW (1) TW200619221A (2)
WO (1) WO2006024517A1 (2)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0316915D0 (en) 2003-07-18 2003-08-20 Glaxo Group Ltd Compounds
US7898642B2 (en) 2004-04-14 2011-03-01 Asml Netherlands B.V. Lithographic apparatus and device manufacturing method
US8097610B2 (en) * 2005-08-26 2012-01-17 Shionogi & Co., Ltd. Derivative having PPAR agonistic activity
EP1978966A4 (en) * 2006-01-23 2010-11-10 Amira Pharmaceuticals Inc TRICYCLIC INHIBITORS OF 5-LIPOXYGENASE
WO2008005908A2 (en) 2006-07-07 2008-01-10 Forest Laboratories Holdings Limited Pyridoimidazole derivatives
BRPI0716539A2 (pt) 2006-09-07 2016-11-01 Emisphere Tech Inc métodos para sintetização de ácido n-(8-[2-hidroxibenzoil]amino) caprílico e de sal de sódio deste
JP2010504367A (ja) 2006-09-26 2010-02-12 グラクソ グループ リミテッド 性機能障害、認知障害、精神病性障害、不安、鬱病などを処置するための５ｈｔ１ａ受容体モジュレーターとしての５−｛２−［４−（２−メチル−５−キノリニル）−ｌ−ピペリジニル］エチル｝キノリノン誘導体
JP2010520293A (ja) * 2007-03-07 2010-06-10 アラントス・フアーマシユーテイカルズ・ホールデイング・インコーポレイテツド 複素環式部分を含有するメタロプロテアーゼ阻害剤
EP2070933A1 (en) * 2007-12-07 2009-06-17 Laboratorios del Dr. Esteve S.A. Tricyclic triazolic compounds
GB0800840D0 (en) 2008-01-17 2008-02-27 Glaxo Group Ltd Novel salt
BRPI0909105A2 (pt) 2008-03-05 2015-08-25 Boehringer Ingelheim Int Derivados de piridina tricíclicos, composição farmacêutica e uso dos mesmos, bem como processos para preparar os ditos compostos e a dita composição farmacêutica
WO2010111626A2 (en) * 2009-03-27 2010-09-30 Takeda Pharmaceutical Company Limited Poly (adp-ribose) polymerase (parp) inhibitors
UY33229A (es) 2010-02-19 2011-09-30 Boehringer Ingelheim Int Derivados de piridina tricíclicos, medicamentos que contienen tales compuestos, su uso y proceso pa ra su preparación
WO2011153359A1 (en) 2010-06-04 2011-12-08 Albany Molecular Research, Inc. Glycine transporter-1 inhibitors, methods of making them, and uses thereof
WO2012154731A1 (en) * 2011-05-08 2012-11-15 Vanderbilt University Substituted 1h-pyrrolo[3,2-c]quinolin-4(5h)-one analogs as positive allosteric modulators of the muscarinic acetylcholine receptor m4
EP2760868B1 (en) 2011-08-17 2018-04-25 Boehringer Ingelheim International GmbH Furo[3,4-c]quinoline derivatives, medicaments containing such compounds, their use and process for their preparation
EP2792679A1 (en) * 2013-04-19 2014-10-22 Laboratorios Del. Dr. Esteve, S.A. Tricyclic triazolic compounds
WO2014209978A1 (en) * 2013-06-24 2014-12-31 Merck Patent Gmbh Imidazole compounds as modulators of fshr and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX9706196A (es) * 1996-08-14 1998-02-28 Pfizer Compuestos triciclicos de piperidinilamino como antagonistas de la sustancia p.
IL124914A (en) * 1997-06-26 2000-10-31 Akzo Nobel Nv Pharmaceutical compositions containing 6-aryl-2,3,5,6-tetrahydroimidazo¬2,1-a¾isoquinoline derivatives and some new such compounds
US6919334B2 (en) * 2002-09-12 2005-07-19 Wyeth Antidepressant azaheterocyclymethyl derivatives of 4,5-dihydroimidazo[1,4,5-de][1,4]benzoxazine
GB0227240D0 (en) * 2002-11-21 2002-12-31 Glaxo Group Ltd Compounds

Also Published As

Publication number Publication date
MA28871B1 (fr) 2007-09-03
NZ553506A (en) 2010-02-26
IL181387A0 (en) 2007-07-04
CN101048414A (zh) 2007-10-03
PE20060653A1 (es) 2006-09-27
TW200619221A (en) 2006-06-16
CN101048414B (zh) 2011-09-07
AU2005279278A1 (en) 2006-03-09
NO20071326L (no) 2007-05-03
KR20070057885A (ko) 2007-06-07
AR053307A1 (es) 2007-05-02
JP2008511574A (ja) 2008-04-17
IL181387A (en) 2011-10-31
US20120022056A1 (en) 2012-01-26
CA2578781A1 (en) 2006-03-09
WO2006024517A1 (en) 2006-03-09
EP1786822A1 (en) 2007-05-23
MX2007002548A (es) 2007-04-24

Similar Documents

Publication Publication Date Title
BRPI0514377A (pt) derivados tricìclicos fundidos para o tratamento de distúrbios psicóticos
SE0302811D0 (sv) Novel compounds
DK1633726T3 (da) Pyrimidinderivater, der er egnede til behandling af CRTH2-formidlede sygdomme
LTC1436271I2 (lt) Fenilpiperazino dariniai, kaip serotonino grįžtamos absorbcijos inhibitoriai
ECSP045255A (es) Cumarinas utiles como biomarcadores
ATE478049T1 (de) Phosphodiesterase-4-inhibitoren, einschliesslich n-substituierter diarylaminanaloga
DK1701941T3 (da) Forbindelser til behandling af sygdomme med celleproliferation
ATE422198T1 (de) Arylsulfonylnaphthalinderivate als 5ht2a- antagonisten
CR8559A (es) Pirazolopirimidinas
PL1863477T3 (pl) 3,4-Podstawione pochodne pirolidyny do leczenia nadciśnienia
IS8122A (is) Aðferð til að framleiða N-útskipt 2-sýanópýrrólídín
NO20081292L (no) Pentasykliske kinaseinhibitorer
NO20070550L (no) Fremgangsmate for fremstilling av pyrrolotriazinforbindelser
DK1756049T3 (da) Fremgangsmåde til fremstilling af 1,4-diphenylazetidinon-derivater
IS8416A (is) Aðferð við framleiðslu á CCR-2 mótlyfi
DK1828154T3 (da) Phenylpiperazinmethanonderivater
DE502004004517D1 (de) Anlage zum herstellen von bauelementen
NO20053809D0 (no) Diarylmetylindenpiperidinderivater,fremgangsmate for fremstilling derav, og anvendelse derav
DK1966217T3 (da) Nye, acyklisk substituerede furopyrimidin-derivater, anvendelsen heraf til behandling af kardiovaskulære sygedomme
EA200602154A1 (ru) Пиридин-4-илэтинилимидазолы и -пиразолы как антагонисты рецептора mglu5
DK1732918T3 (da) Hidtil ukendte pyrrolidin 3,4 dicarboxamidderivater
DK1519936T3 (da) Fremgangsmåde til fremstilling af nevirapin
CR8162A (es) Piridinylanilides
IS7924A (is) Setnar anilín afleiður
EP1610360A4 (en) DUMMY WAFER

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2260 DE 29/04/2014.